Time Course of 5-HT2A Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Positron Emission Tomography

MDL 100,907 is a potent and selective antagonist of 5-HT2A serotonin receptors. Animal studies suggest that MDL 100,907 may behave as an atypical antipsychotic drug. Positron emission tomograph (PET) using [11C]NMSP as the radiotracer was used to define the time course of 5-HT2 receptor occupancy in the human frontal cerebral cortex after a single oral dose of MDL 100,907 (10 or 20 mg) in nine healthy subjects. After the baseline scan each subject was studied three times post dosing at various time points. 5-HT2 occupancies were in the range of 70 and 90% after each dose. While the occupancy remains in this range over 24 hours after 20 mg MDL 100,907, it decreases by about 20% at 24 hours compared to the timepoint at 8 hours, when only 10 mg are administered (p < 0.05). Our results should allow determination of the appropriate dosing regimen for future trials in schizophrenic patients.

[1]  H. Meltzer,et al.  The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. , 1989, Psychopharmacology bulletin.

[2]  M. Millan,et al.  Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptormediated phosphoinositide (PI) turnover by clozapine in the rat: A comparison to other antipsychotics , 1994, Neuroscience Letters.

[3]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  Alan A. Wilson,et al.  Localization of serotonin 5‐HT2 receptors in living human brain by positron emission tomography using N1‐([11C]‐methyl)‐2‐BR‐LSD , 1987, Synapse.

[5]  C. J. Schmidt,et al.  5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. , 1992, European journal of pharmacology.

[6]  C. Lemaire,et al.  Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  M. Kuhar,et al.  In vivo binding of 3H-N-methylspiperone to dopamine and serotonin receptors. , 1987, Life sciences.

[8]  J. Krystal,et al.  Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  A. Gjedde,et al.  Reply to Swart and Korf , 1989 .

[10]  J. Palacios,et al.  Dopamine receptors in human brain: Autoradiographic distribution of D2 sites , 1989, Neuroscience.

[11]  J. Maloteaux,et al.  Characterization and regional distribution of serotonin S2-receptors in human brain , 1983, Brain Research.

[12]  C Crouzel,et al.  [18F]setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. , 1988, European journal of pharmacology.

[13]  A. Wilson,et al.  An improved synthesis of (3-N-[11C]methyl)spiperone. , 1986, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[14]  A Carlsson,et al.  The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[15]  P S Goldman-Rakic,et al.  Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Ticku,et al.  Central cardiovascular effects of baclofen in spontaneously hypertensive rats. , 1987, Life sciences.

[17]  G. Sedvall,et al.  Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. , 1988, Archives of general psychiatry.

[18]  J. Palacios,et al.  Serotonin receptors in the human brain—IV. Autoradiographic mapping of serotonin-2 receptors , 1987, Neuroscience.

[19]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[20]  J. Ferrer,et al.  Ontogeny of dopamine, serotonin and spirodecanone receptors in rat forebrain--an autoradiographic study. , 1985, Brain research.

[21]  J M Links,et al.  3H-3-N-methylspiperone labels D2 dopamine receptors in basal ganglia and S2 serotonin receptors in cerebral cortex , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  Alan C. Evans,et al.  MRI-PET Correlation in Three Dimensions Using a Volume-of-Interest (VOI) Atlas , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  C. J. Schmidt,et al.  The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. , 1995, European journal of pharmacology.

[24]  M. Folstein,et al.  EFFECTS OF AGE ON DOPAMINE AND SEROTONIN RECEPTORS MEASURED BY POSITRON TOMOGRAPHY IN THE LIVING HUMAN BRAIN , 1984, Science.

[25]  A. Gjedde,et al.  Quantification of Neuroreceptors in the Living Human Brain. I. Irreversible Binding of Ligands , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.